We are live on ! Find out more
GANX icon

Gain Therapeutics

22 hedge funds and large institutions have $5.54M invested in Gain Therapeutics in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,527% more call options, than puts

Call options by funds: $289K | Put options by funds: $11K

157% more capital inflows, than outflows

Capital inflows: $461K | Capital outflows: $179K

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

5% more funds holding

Funds holding: 21 → 22 (+1)

0.48% less ownership

Funds ownership: 10.16% → 9.68% (-0.48%)

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

Holders
22
Holders Change
+1
Holders Change %
+4.76%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
6
Closed
2
Calls
$289​K
Puts
$11​K
Net Calls
+$278​K
Net Calls Change
+$278​K

GANX Hedge Fund Activity: Q1 2023 in Review

22 of the 6,286 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q1 2023, worth a combined $5.54M — up 47% from $3.78M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new GANX positions and 2 closed out — a net gain of 2 holders — while 5 added to existing stakes and 6 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $215K. The largest seller was CM Management, cutting an estimated $81.7K.

  • 22 institutional investors held Gain Therapeutics (GANX) as of Q1 2023, up from 21 in Q4 2022.
  • Funds reported $5.54M of Gain Therapeutics stock for Q1 2023, up 47% quarter-over-quarter.
  • 4 funds opened new Gain Therapeutics positions in Q1 2023 and 2 closed out, a net change of +2 holders.
  • The largest Gain Therapeutics buyer in Q1 2023 was Vanguard Group, an estimated $215K added.
  • The largest Gain Therapeutics seller in Q1 2023 was CM Management, an estimated $81.7K sold.

Based on aggregated 13F filings for Q1 2023.